Vera Therapeutics Q2 net loss $76.5M; on track to submit atacicept BLA in Q4 2025

Vera Therapeutics, Inc.

2025-Q2 EPS reported -$2.01

Net loss $76.5M ($1.20 per share) vs $33.7M ($0.62) year-over-year; cash $556.8M as of June 30, 2025.
Positive ORIGIN 3 trial: 46% proteinuria reduction with atacicept; 42% vs placebo (p<0.0001).
BLA submission for accelerated approval of atacicept in IgAN expected Q4 2025; commercial launch targeted 2026.
Secured up to $500M credit facility with Oxford Finance, extending cash runway past potential launch.
Initiated PIONEER basket trial for atacicept in expanded IgAN, pMN, FSGS, and MCD populations.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.